Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyAmeriHealth Select Drug Formulary Prior Auth | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAmeriHealthPolicy N/A

    Select Drug Program Formulary

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document describes AmeriHealth's Select Drug Program formulary structure, coverage processes (including prior authorization and safety edits), and ACA preventive medication coverage guidance for members and providers affected by AmeriHealth pharmacy benefits.

    Policy Summary
    PayerAmeriHealth
    PolicySelect Drug Program Formulary
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization via ePA (SureScripts™) or fax to 1-888-671-5285 with clinical justification to request coverage beyond limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ePAePA supported
    90Opioid MME PA threshold
    $10kClaims dollar PA threshold
    75%Refill-too-soon rule
    extensivePA-listed drugs

    Formulary Coverage Rules & Drug Listings

    Coverage criteria and utilization management

    Covered when specified by member benefits and medical necessity; ACA preventive medications available at $0 cost-share when criteria met.

    Inclusion on the Select Drug Program formulary does not guarantee coverage; coverage is determined by member-specific benefits and medical necessity determinations.
    Certain preventive medications specified under the Affordable Care Act are covered without member cost‑sharing when provided by a participating pharmacy, subject to member eligibility and plan variation; examples include aspirin in pregnancy, selected bowel preparations, tamoxifen for breast cancer prevention, contraceptives, fluoride for children, folic acid, tobacco cessation medications, selected statins, HIV PrEP, and specified vaccines.

    See formulary preventive medication list for product-level details.

    Utilization management edits (quantity limits, day‑supply limits, age limits, refill-too-soon edits) and safety edits (MME/stimulant cumulative limits) apply; coverage beyond these limits requires prior authorization with clinical justification.

    Coverage Criteria and Processes

    Policy Summary
    PayerAmeriHealth
    PolicySelect Drug Program Formulary
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization via ePA (SureScripts™) or fax to 1-888-671-5285 with clinical justification to request coverage beyond limits.
    SourceLink
    On This Page
    Formulary Coverage Rules & Drug ListingsTier Codes, Requirement Codes, and ThresholdsActions Providers Must Take to Request Coverage or ExceptionsFormulary Terms & Legend

    Prior authorization and exception criteria summarized from the document excerpt:

    Prior authorization is required for opioid prescriptions that exceed 90 MME per day.

    MME-based limit applies across opioid products and is calculated from total daily opioid use.

    Prior authorization is required for stimulant claims that exceed the specified cumulative daily dose thresholds by active ingredient (examples: amphetamine/amphetamine-dextroamphetamine/dextroamphetamine/methamphetamine = 60 mg/day; lisdexamfetamine = 70 mg/day; dexmethylphenidate = 40 mg/day; methylphenidate = 72 mg/day; serdexmethylphenidate = 52.3 mg/day).
    Prior authorization requests must be submitted by the prescribing provider via electronic prior authorization (ePA, e.g., SureScripts™) or fax (1-888-671-5285); the PBM reviews the request (clinical pharmacist or medical director) and communicates approval or denial via fax/telephone/letter. ePA may approve in real time.
    Formulary tier exception requests require documentation of trial of, or contraindication to, at least three formulary alternatives when applicable; some tiers/plans and certain tiers (generic, preferred brand, specialty) are not eligible for tier exceptions; submit exception form to 1-888-671-5285.
    If a prior authorization or exception is denied, the member or provider (with consent) may file an appeal; denials include appeal contact details and providers are encouraged to supply additional clinical information.
    An extensive alphabetized list of specific drugs and formulations require prior authorization; prior authorization applies to all formulations (tablet, capsule, oral suspensions) of listed drugs.

    Prior authorization: listed products (partial)

    Partial enumerated drug list subject to prior authorization; entries map product names to numbered alternative tokens in the list.

    Partial PA product listing

    • Abilify (and mapped alternatives 1,2,3) — listed in PA product index.
    • Absorica LD (and mapped alternatives) — listed in PA product index.
    • Multiple additional brand and generic drugs listed alphabetically (extensive list in source).

    Sample drug-tier-requirement entries (Antibiotics & other drugs)

    Examples of drug-specific tier and requirement entries (partial list; continues across chunks).

    Altabax — Tier: NPD; Requirements: PA.
    Arikayce — Tier: NPD, SP; Requirements: PA.
    Cresemba — Tier: NPD; Requirements: PA, QL, Q/T.
    Daklinza — Tier: NPD, SP; Requirements: PA, QL, Q/T.
    Doxycycline hyclate DR 80mg — Tier: G; Requirements: PA.
    Daraprim Tab — Tier: NPD; Requirements: PA.
    Descovy — Tier: NPD (some strengths ACA); Requirements: QL; certain strengths require PA.

    Partial coverage entries

    This fragment enumerates drugs with tier and any associated requirements/limits.

    Combivir — Tier: NPD; Requirements: none indicated in excerpt (listed among antibiotics section).
    Cresemba — Tier: NPD; Requirements: PA, QL, Q/T.
    Daklinza — Tier: NPD, SP; Requirements: PA, QL, Q/T.
    Dificid tab/susp — Tier: NPD; Requirements: QL, PA.
    Diflucan tab/susp — Tier: NPD; Requirements: PA.

    Selected drug coverage examples

    Formulary stance and coverage controls for listed drugs in this segment.

    Sofosbuvir-velpatasvir 400-100 mg — Tier: NPD, SP; Requirements: PA, QL; Coverage stance: covered with criteria.

    Seysara coverage

    Seysara — Tier: NPD; Requirements: Q/T, PA; Coverage stance: covered with criteria.

    Sample drug requirement nodes

    Per-drug coverage controls shown as abbreviations following drug entries; examples from this section include:

    Fareston — Tier: NPD; Requirements: none listed in this excerpt (example entry).
    Farydak — Tier: NPD, SP; Requirements: PA, LDD (Limited Distribution Drug).
    Gleevec (example mapping in this section) — Tier: NPD, SP; Requirements: PA.
    Tagrisso — Tier: NPD, SP; Requirements: PA, QL.

    Sample drug entries and controls

    Per-drug entries include tier and any requirements/limits. Examples from this segment:

    Ajovy — Tier: NPD, SP; Requirements: PA.
    Xalkori — Tier: NPD, SP; Requirements: PA; some entries include QL and 5DS where specified.
    amantadine (Arymo ER) — Tier: NPD; Requirements: PA, QL, MME.
    Ambien / Ambien CR — Tier: NPD; Requirements: PA, QL.
    Amerge — Tier: NPD; Requirements: PA, QL, AL (age limit).
    Evekeo (amphetamine caps) — Tier: NPD; Requirements: PA, QL.

    Per-drug criteria examples

    Per-drug coverage controls (examples from excerpt):

    Dexedrine — Tier: NPD; Requirements: PA, QL, 5DS, MME.
    Diclofenac cap 25mg — Tier: G; Requirements: PA, QL.
    Emgality (300mg) Prefilled Pen — Tier: PB; Requirements: PA, QL.
    Embadel/Exalgo — Tier: NPD; Requirements: PA, QL, MME.
    Hydrocodone ER — Tier: G; Requirements: PA, QL, MME.

    Sample drug criteria from listing

    Drug-specific tier and utilization controls (sample entries from this portion of the formulary):

    Lexapro — Tier: NPD; Controls: PA.
    levetiracetam ER — Tier: G; Controls: none listed in excerpt.
    Lortab — Tier: NPD; Controls: QL, 5DS, PA.
    Morphine IR — Tier: G; Controls: QL, 5DS, MME.
    Narcan 4mg spray — Tier: PB; Controls: QL.

    Formulary coverage controls (excerpt)

    Drugs listed include an associated tier and one or more requirement/limit flags determining coverage controls.

    Tier assignment: drugs are assigned tiers (NPD, G, PB, LCG, SP) which influence preferred status and cost‑sharing.
    PA flag: when 'PA' appears next to a drug, prior authorization is required for coverage of that formulation.
    QL flag: when 'QL' appears, quantity limits apply and claims should be adjudicated accordingly.
    SP flag: 'SP' indicates Specialty Drug designation and may require specialty pharmacy handling or additional controls.
    AL flag: 'AL' indicates an age/day-supply limit applies to the listed formulation.
    MME flag: presence of 'MME' indicates MME-based opioid controls apply (numeric thresholds shown elsewhere in the policy).

    Sample coverage controls by drug

    Per-drug entries include tier and any requirements/limits. Examples from this segment:

    Vraylar — Tier: NPD; Requirements: PA, QL, AL.
    Vyvanse — Tier: NPD; Requirements: PA, QL.
    Xyrem — Tier: NPD, SP; Requirements: PA, QL.
    Zohydro ER — Tier: NPD; Requirements: PA, QL, MME.

    Extracted coverage indicators from listed drugs

    Formulary entries indicate coverage stance via tier and requirements; many non-preferred or specialty agents require prior authorization.

    Cozaar — Tier: NPD; Requirements: PA.
    Crestor — Tier: NPD; Requirements: PA (some lines show none in other entries).
    Demadex — Tier: NPD; Requirements: PA.
    digoxin — Tier: G; Requirements: PA (in at least one entry).
    diltiazem HCl CD — Tier: NPD; Requirements: PA.

    sample drug-specific annotations

    Per-drug coverage annotations in this section (examples):

    Norpace — Tier: NPD; Requirements: PA.
    Novoeight — Tier: PB, SP; Requirements: PA.
    sildenafil citrate 25/50/100 mg — Tier: LCG/G/SP; Requirements: QL, PA (strength-specific).
    Verquvo — Tier: NPD; Requirements: PA, QL.
    Xarelto — Tier: PB; Requirements: none listed in excerpt.

    Coverage entries

    The excerpt is a drug list mapping specific dermatology/topical drugs to tiers and any associated requirements or limits.

    Absorica LD — Tier: NPD/G; Requirements: PA; may include claim dollar limit annotation in some entries.
    Acanya — Tier: NPD; Requirements: PA.
    Adapalene 0.1% lotion — Tier: NPD/G; Requirements: AL (age limit).
    Calcipotriene foam — Tier: NPD; Requirements: PA.
    Bimzelx Inj — Tier: NPD, SP; Requirements: PA.
    Dupixent — Tier: PB, SP (also listed as G, SP in some lines); Requirements: PA.
    Filsuvez Gel 10% — Tier: NPD, SP / LCG; Requirements: PA, QL.
    Hydrocortisone Lot 2% — Tier: NPD; Requirements: PA.
    Imiquimod Cream 3.75% Pump — Tier: NPD; Requirements: PA.
    Klisyri Oint 1% — Tier: NPD; Requirements: PA.

    Tier Codes, Requirement Codes, and Thresholds

    Formulary index samplemixed
    Formulary index listing (partial: drugs beginning with Z shown in this chunk)
    Utilization thresholds requiring prior authmixedCovered
    MME>90Opioid daily morphine milligram equivalent exceeds 90 MME — prior authorization required
    STIM_HIGH_DOSEStimulant cumulative daily dose exceeds listed threshold for specific active ingredient — prior authorization required
    Utilization thresholds requiring prior auth (details)mixed
    MME>90Prior authorization is required for an opioid dose that exceeds 90 MME per day (chunk 18)
    AMPHETAMINE>60MGAmphetamine high cumulative daily dose = 60mg/day (chunk 20)
    AMPH-DEXTRO>60MGAmphetamine-Dextroamphetamine high cumulative daily dose = 60mg/day (chunk 20)
    DEXTROAMPHETAMINE>60MGDextroamphetamine high cumulative daily dose = 60mg/day (chunk 20)
    LISDEXAMFETAMINE>70MGLisdexamfetamine high cumulative daily dose = 70mg/day (chunk 20)
    METHAMPHETAMINE>60MGMethamphetamine high cumulative daily dose = 60mg/day (chunk 20)
    DEXMETHYLPHENIDATE>40MGDexmethylphenidate high cumulative daily dose = 40mg/day (chunk 20)
    METHYLPHENIDATE>72MGMethylphenidate high cumulative daily dose = 72mg/day (chunk 20)
    SERDEXMETHYLPHENIDATE>52.3MGSerdexmethylphenidate high cumulative daily dose = 52.3mg/day (chunk 20)
    Formulary tiers and abbreviations (legend)mixed
    GGeneric
    NPDNon-preferred drug
    SPSpecialty drug
    LCGLow-cost generic
    PBPreferred brand
    ACA$0 Preventive drug
    Tier designations (sample)mixed
    Drug tier designations (e.g., NPD, G, PB, LCG) appear but no standard billing codes provided in this fragment
    Formulary tier codesmixed
    NPDNon Preferred Drug
    GGeneric
    PBPreferred Brand
    SPSpecialty Drug
    LCGLow Cost Generic
    Formulary tier codes presentmixed
    NPDNon Preferred Drug (tier indicator)
    GGeneric (tier indicator)
    PBPreferred Brand (tier indicator)
    Sample drug entries (tier examples)mixed
    TagrissoTagrisso — TIER = NPD, SP; REQUIREMENTS/LIMITS = PA, QL (chunk 120)
    FarestonFareston — TIER = NPD; example entries in chunk 108
    Formulary abbreviations and controlsmixed
    PAPrior Authorization
    QLQuantity Limits Apply
    SPSpecialty Drug
    NPDNon Preferred Drug
    GGeneric
    PBPreferred Brand
    5DSDay Supply Limit
    MMEMorphine Milligram Equivalent
    LCGLow Cost Generic
    Formulary flags and utilization codesmixed
    PAPrior Authorization
    QLQuantity Limits Apply
    5DSDay Supply Limit
    MMEMorphine Milligram Equivalent
    LDDLimited Distribution Drug
    SPSpecialty Drug
    NPDNon Preferred Drug
    GGeneric
    PBPreferred Brand
    LCGLow Cost Generic
    1–10 of 12
    1/2
    Utilization acronym definitionsmixed
    PAPrior Authorization
    QLQuantity Limits Apply
    5DSDay Supply Limit
    MMEMorphine Milligram Equivalent
    Formulary requirement codesmixed
    PAPrior Authorization
    QLQuantity Limits Apply
    SPSpecialty Drug
    ALAge Limit
    MMEMorphine Milligram Equivalent
    5DSDay Supply Limit
    Formulary requirement and tier codesmixed
    PAPrior Authorization
    QLQuantity Limits Apply
    SPSpecialty Drug
    NPDNon Preferred Drug
    PBPreferred Brand
    GGeneric
    Drug list entries (no billing codes)mixed
    N/ANo CPT/HCPCS/ICD-10/NDC codes are present in these chunks; entries are drug-name and tier metadata.
    Formulary annotations and requirement codesmixed
    PAPrior Authorization
    QLQuantity Limits Apply
    ALDay Supply Limit
    LDDLimited Distribution Drug
    SPSpecialty Drug
    PBPreferred Brand
    NPDNon-Preferred Drug
    GGeneric
    LCGLow Cost Generic
    Formulary requirement abbreviationsmixed
    PAPrior Authorization
    QLQuantity Limits Apply
    ALAge Limit
    SPSpecialty Drug
    LCGLow Cost Generic
    NPDNon Preferred Drug
    inv-31: prior authorization dollar/MME thresholds — $10,000 claim review threshold; 90 MME/day opioid prior authorization threshold
    Claim dollar prior authorization thresholdClaims exceeding $10,000 require prior authorization review
    Opioid MME prior authorization thresholdPrior authorization required for opioid doses > 90 MME/day
    Purpose of dollar/MME limitsClaim dollar limits and MME thresholds trigger clinical review to confirm medical necessity and safety
    inv-32: Amphetamine family high cumulative daily dose — 60 mg/day (AMP/AMP-DEX/DEX/METH)
    Affected active ingredients/classesAmphetamine, amphetamine-dextroamphetamine, dextroamphetamine, methamphetamine
    High cumulative daily dose threshold60 mg/day cumulative amphetamine-equivalent
    Program actionClaims exceeding this cumulative stimulant threshold require prior authorization
    inv-33: Lisdexamfetamine high cumulative daily dose — 70 mg/day
    Drug class/exampleLisdexamfetamine (Vyvanse and generics)
    High cumulative daily dose threshold70 mg/day
    Program actionPrior authorization required for claims exceeding 70 mg/day cumulative dose
    inv-34: Dexmethylphenidate high cumulative daily dose — 40 mg/day
    Drug class/exampleDexmethylphenidate (Focalin® IR/XR and generics)
    High cumulative daily dose threshold40 mg/day
    Program actionPrior authorization required for claims exceeding 40 mg/day cumulative dose
    inv-35: Methylphenidate high cumulative daily dose — 72 mg/day
    Drug class/exampleMethylphenidate products (Ritalin®, Concerta®, Daytrana®, and generics)
    High cumulative daily dose threshold72 mg/day
    Program actionPrior authorization required for claims exceeding 72 mg/day cumulative dose
    inv-36: Serdexmethylphenidate high cumulative daily dose — 52.3 mg/day
    Drug class/exampleSerdexmethylphenidate (Azstarys™)
    High cumulative daily dose threshold52.3 mg/day
    Program actionPrior authorization required for claims exceeding 52.3 mg/day cumulative dose
    inv-37: Opioid MME prior authorization threshold — 90 MME/day
    Opioid prior authorization triggerPrior authorization required when total opioid dose exceeds 90 MME/day
    MME definition/useMME converts various opioid potencies to a morphine-equivalent to assess daily opioid exposure
    ScopeApplies to opioid products containing listed active ingredients; claims above threshold require review
    inv-38: Quantity/limit abbreviations — PA, QL, AL, LDD, 5DS, R, Q/T, MME
    PAPrior Authorization
    QLQuantity Limits Apply
    ALAge Limit
    LDDLimited Distribution Drug
    5DSDay Supply Limit (5-day supply indicator)
    RRequires Rider
    Q/TQuantity Over Time
    MMEMorphine Milligram Equivalent
    inv-39: Quantity Limits (QL) examples — Applied to several drugs (e.g., Descovy, emtricitabine-tenofovir formulations, fidaxomicin)
    Example drugs with QLDescovy (listed with QL), emtricitabine‑tenofovir formulations (QL noted), fidaxomicin (QL noted)
    ContextQuantity Limits (QL) flags are applied to specified formulations in the drug list
    Action when exceededClaims exceeding specified quantity limits require prior authorization or will be subject to denial/override processes
    inv-40: Quantity Limits / Quantity Over Time — QL and Q/T examples (e.g., Qualaquin QL; Seysara Q/T)
    QL exampleQualaquin (example of QL applied in list)
    Q/T exampleSeysara — listed with Quantity Over Time (Q/T) and PA
    ImplicationQ/T indicates quantity restrictions measured over a defined time interval; exceeding limits may require prior authorization
    inv-41: Quantity Limits (QL) — Applied to many listed drugs (QL indicated next to entries)
    General QL usageQuantity Limits (QL) are applied to many listed drugs as indicated in the requirements/limits field
    Examples of QL flagged productsTopiramate sol (QL, PA), sildenafil strengths (QL indicated for 25/50/100 mg), various specialty agents
    EnforcementQL flags should be enforced at claim adjudication; overrides require PA or documented exception
    inv-42: Day supply / quantity thresholds — specified per drug as QL, 5DS, AL where applicable
    Types of day‑supply/quantity indicatorsQL (Quantity Limits), 5DS (Day Supply Limit), AL (Age Limit)
    Per‑drug specificationDay supply or quantity thresholds are specified per drug row in the formulary where applicable (values vary by product)
    Enforcement noteThese limits are implemented at claim adjudication and may require PA or exception for coverage beyond limits
    inv-43: Examples of thresholds applied — QL, 5DS day supply limits, and MME constraints for opioid products
    Examples of applied thresholdsQL (weekly or product-specific), 5DS day supply limits, and MME constraints on opioid products
    Drug examplesendocet and other combination opioids shown with 5DS, QL, MME; morphine IR shown with QL, 5DS, MME
    Operational effectExceeding these thresholds will trigger safety edits, possible POS rejects, or prior authorization requirements
    inv-44: Examples of controls applied — Many opioid products show QL, 5DS, MME; select products require PA
    Controls commonly applied to opioid productsMany opioid entries include QL, 5DS, and MME restrictions; select opioid products also require PA
    ExamplesExalgo, Embeda/Exalgo, hydrocodone ER, Nucynta ER show PA, QL, and MME indicators in the listing
    Resulting workflowClaims for these products undergo MME calculation and may be denied or require PA if thresholds exceeded
    inv-45: Day supply and MME limits — Entries may include 5DS and MME restrictions (specific numeric thresholds not present in this excerpt)
    Common limit types noted5DS (5-day supply) and MME (morphine milligram equivalent) appear repeatedly as controls
    Specific product notesZolpidem tartrate lines show PA and QL (10 mg only); tramadol entries list QL and MME
    EnforcementNumeric day-supply/MME restrictions are applied per drug row; some numeric values are present for specific products (see opioid MME and stimulant thresholds)
    inv-46: Specific quantity or dose limits noted — Examples include '5DS' and 'MME'; zolpidem tartrate noted PA, QL (10mg only)
    Examples of specific limit notations'5DS' = 5 day supply; 'MME' indicates morphine milligram equivalent limits; zolpidem tartrate noted PA, QL (10 mg only)
    PurposeThese notations indicate the type of utilization control applied to that drug/formulation on the formulary
    Action requiredWhen these flags appear on a claim, adjudication enforces the corresponding limit or routes to PA workflow
    inv-47: Quantity Limits (QL) — Applied where indicated; specific numeric thresholds not provided in these chunks
    QL indicator usage'QL' appears next to many product strengths and formulations to indicate quantity limits apply
    Strength-specific QL examplesSildenafil 25/50/100 mg lines show QL indicators in the listing
    Implementation noteQL flags should be interpreted per product row in the drug list during claim adjudication
    inv-48: Quantity Limit indicator — QL applied to specific strengths/products (e.g., sildenafil 25/50/100mg)
    QL applied to specific strengths/productsSildenafil citrate 25/50/100 mg lines show QL applied to those strengths
    ExamplesSildenafil 20 mg tab/susp also shows PA; sildenafil strengths 25/50/100 mg show QL
    InterpretationStrength-level QL indicators denote quantity constraints that may vary by strength/formulation

    Actions Providers Must Take to Request Coverage or Exceptions

    Prior Authorization

    Prior authorization required for certain drugs and claims > $10,000

    Prior authorization is required for certain covered drugs to confirm medical necessity and appropriateness; claim dollar limits trigger review for prescriptions exceeding $10,000 and require prior authorization. Approvals may be time-limited and will require reauthorization when they expire.

    • Without prior authorization, the prescription will not be covered at retail or mail-order pharmacy.
    • Prior authorization reviews may take up to two business days after complete information is received; incomplete information may delay the decision.
    • Some prior authorizations have limited timeframes (e.g., 6–12 months) and require resubmission after expiration.
    Prior Authorization

    PA required for opioid >90 MME/day and high-dose stimulants

    Prior authorization is required for opioid prescriptions that exceed 90 MME per day; stimulant prescriptions that exceed the listed cumulative daily dose thresholds by active ingredient also require prior authorization.

    • Opioid MME threshold: prior authorization required >90 MME/day.
    • Stimulant cumulative daily dose thresholds (examples): amphetamine 60 mg/day; amphetamine–dextroamphetamine 60 mg/day; dextroamphetamine 60 mg/day; lisdexamfetamine 70 mg/day; dexmethylphenidate 40 mg/day; methylphenidate 72 mg/day; serdexmethylphenidate 52.3 mg/day.
    Documentation Required

    Request PA for safety-edit exceptions with clinical justification

    Providers may request coverage for prescriptions that fall outside age or quantity safety edits by submitting a prior authorization with clinical justification; incomplete clinical information may delay review.

    • Age limits: provider may request coverage when prescription falls outside FDA age guidance by submitting PA with supporting clinical rationale.
    • Quantity limits: if member requires more than the specified quantity limit, the provider must submit a PA; quantity-limit overrides may be time-limited.
    • Safety edits include age limits, quantity limits, MME limits and cDUR that may prompt counseling or require PA.
    Prior Authorization

    How to submit PA — ePA (SureScripts™) or fax to 1-888-671-5285

    Submit prior authorization requests via an electronic prior authorization (ePA) platform such as SureScripts™ or by faxing a completed prior authorization form or a letter of medical necessity to the PBM at 1-888-671-5285; ePA can approve in real time and decisions are communicated by fax/telephone/letter.

    • If a clinical pharmacist cannot approve the request, it will be escalated to a medical director for review.
    • If approved, the provider is notified via fax/telephone and the adjudication system is coded; if denied, provider and member are notified and appeal instructions are provided.
    Prior Authorization

    PA triggers — opioids >90 MME/day and stimulant cumulative limits

    Prior authorization is triggered for opioids exceeding 90 MME/day and for stimulant claims that exceed the cumulative dose limits specified by active ingredient; claims above these thresholds require prior authorization before coverage.

    • Opioid products containing listed opioid active ingredients are subject to the 90 MME/day PA threshold.
    • Stimulant claims exceeding per-ingredient cumulative limits (see documented thresholds) will require PA.
    Denial Risk

    cDUR may reject/flag claims at point-of-sale; pharmacist review required

    Concurrent Drug Utilization Review (cDUR) may reject or flag claims at point-of-sale; the dispensing pharmacist may review and, when appropriate, override rejections after consulting the prescriber.

    • cDUR may generate POS rejects or messages for drug–drug interactions or therapy duplication.
    • Pharmacist may review with provider and can override most edits if clinically appropriate.
    Documentation Required

    Formulary exception requests — trial of ≥3 alternatives; fax to 1-888-671-5285

    Tier exception (formulary exception) requests may be submitted when there has been trial of, or contraindication to, at least three formulary alternatives; providers must fax the completed formulary exception request form to 1-888-671-5285 and note that some tiers/plans or certain tiers (generic, preferred brand, specialty) may be ineligible for exceptions.

    • If exception approved, the non-preferred drug will be covered at the preferred brand or generic cost-share level as applicable.
    • Tier exceptions are not available under some plans—refer to the member benefit booklet for eligibility.
    Prior Authorization

    PA applies to all formulations of listed drugs

    Prior authorization applies to all formulations (tablet, capsule, oral suspension, etc.) of the drugs listed in the formulary drug rows; providers must obtain PA for any formulation indicated with 'PA'.

    • The PA designation on a drug row applies to all formulations of that drug.
    • Check the drug list entries for PA flags next to specific products and formulations.
    Prior Authorization

    Examples: Doxycycline hyclate DR 80mg and Daraprim Tab require PA

    Prior authorization applies to listed drugs shown with 'PA' in the requirements/limits column (examples in the list include Doxycycline hyclate DR 80mg and Daraprim Tab).

    • Doxycycline hyclate DR 80mg is listed with REQUIREMENTS/LIMITS = PA.
    • Daraprim Tab is listed with REQUIREMENTS/LIMITS = PA.
    Note
    Note
    Prior Authorization

    Mavyret requires PA plus quantity limits (QL, Q/T)

    Some products are subject to both prior authorization and quantity controls; for example, Mavyret is listed with REQUIREMENTS/LIMITS = PA, QL, Q/T and requires prior authorization and quantity/quantity-over-time enforcement.

    • Mavyret entries show PA, QL, and Q/T — providers must request PA and adhere to quantity/quantity-over-time limits if applicable.
    Prior Authorization

    Rezurock (NPD, SP) requires PA and QL

    Rezurock is listed as Non-Preferred and Specialty and requires prior authorization and quantity limits (PA, QL) for coverage.

    • Rezurock entries indicate TIER = NPD, SP and REQUIREMENTS/LIMITS = PA, QL.
    Prior Authorization

    Seysara requires PA and Quantity Over Time (Q/T)

    Seysara is listed as Non-Preferred and requires prior authorization and Quantity Over Time (Q/T) controls (REQUIREMENTS/LIMITS = Q/T, PA).

    • Seysara entries show REQUIREMENTS/LIMITS = Q/T, PA — providers must submit PA and adhere to Q/T limits.
    Prior Authorization

    Sofosbuvir–velpatasvir 400/100 mg requires PA and QL

    Sofosbuvir–velpatasvir 400/100 mg is listed as Non-Preferred Specialty and requires prior authorization and quantity limits (PA, QL).

    • Sofosbuvir-velpatasvir 400-100mg entries indicate REQUIREMENTS/LIMITS = PA, QL and tier = NPD, SP.
    Prior Authorization

    vancomycin formulations may require PA and QL; specialty/LDD noted

    Some vancomycin formulations are subject to prior authorization and quantity limits; select vancomycin entries indicate PA/QL and may be designated specialty or limited distribution requiring special handling.

    • Review the drug list for vancomycin rows showing REQUIREMENTS/LIMITS = PA, QL and SP/LDD designations where present.
    Prior Authorization

    Viread specialty formulation requires PA and QL

    Viread entries include a specialty formulation that requires prior authorization and quantity limits (PA, QL) when designated as specialty.

    • Viread shown with TIER = NPD, SP and REQUIREMENTS/LIMITS = PA, QL for specialty formulations.
    Note

    Legend: PA = Prior Authorization; QL, SP, LDD and other abbreviations

    The formulary legend defines PA = Prior Authorization and common requirement abbreviations such as QL = Quantity Limits Apply, LDD = Limited Distribution Drug, SP = Specialty Drug; providers should use these flags on drug rows to determine actions required.

    • PA = Prior Authorization; QL = Quantity Limits Apply; SP = Specialty Drug; LDD = Limited Distribution Drug; 5DS = Day Supply Limit; MME = Morphine Milligram Equivalent.
    • The legend and drug rows indicate which utilization controls (PA, QL, 5DS, AL, Q/T, MME, LDD, SP) apply to each product.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Formulary Terms & Legend

    inv-88: Formulary — list of prescription medications chosen for safety, cost, and effectiveness; drugs organized by category and cost tiers
    Formulary definitionA formulary is a list of prescription medications chosen for safety, cost, and effectiveness; drugs are organized by category and cost tiers.
    GovernanceThe Pharmacy and Therapeutics Committee reviews which medications will be covered and the approval criteria.
    ScopeIncludes both brand and generic prescription medications and assigns tier placement that affects cost-share.
    inv-89: Tiers, Specialty, and Authorized Generics — tier definitions and specialty criteria
    Tier definitionsLow-Cost Generic (LCG), Generic (G), Preferred Brand (PB), Non‑Preferred Drug (NPD), Specialty (SP)
    Specialty criteriaSpecialty drugs meet criteria like complex storage, monitoring, or treatment of rare/complex conditions and often have higher cost‑sharing
    Authorized GenericsAuthorized generics are treated as brand-name for cost‑sharing and may be non‑preferred
    inv-90: PBM role — independent PBM administers drug program, network pharmacies, and utilization management
    PBM roleAn independent PBM administers the prescription drug program, provides network pharmacies, and manages utilization controls like prior authorization and quantity limits
    MonitoringPBM monitors prescribing patterns and enforces safety procedures such as PA, age limits, and quantity limits
    inv-91: MME — Morphine Milligram Equivalent definition
    MME definitionMorphine Milligram Equivalent (MME) converts various opioid potencies to a morphine‑equivalent to assess total daily opioid exposure
    Use in programMME is used to identify opioid claims requiring additional caution or prior authorization when the daily MME exceeds the program threshold
    inv-92: cDUR — Concurrent Drug Utilization Review definition
    cDUR definitionConcurrent Drug Utilization Review (cDUR) — automated claim checks for interactions and therapy duplication that may reject or flag claims at point‑of‑sale
    Pharmacist actionDispensing pharmacist may review and override certain edits with provider consultation when appropriate
    inv-93: prior authorization scope — PA applies to all formulations of the listed drugs
    PA scopePrior authorization applies to all formulations of listed drugs (tablet, capsule, oral suspensions, etc.) when PA is indicated
    List examplesExtensive alphabetized drug list in the formulary denotes products requiring PA across formulations
    inv-94: Brand vs Generic display — formatting guidance for brand vs generic names
    Brand vs generic display ruleBrand-name medications start with an uppercase letter and are bold; generic medications are shown in lowercase and italic
    PurposeFormatting helps users identify brand vs generic on the formulary list
    inv-95: Tier legend — G, NPD, SP, LCG, PB, ACA
    Tier legend abbreviationsG = Generic; NPD = Non‑Preferred Drug; SP = Specialty Drug; LCG = Low‑Cost Generic; PB = Preferred Brand; ACA = $0 Preventive Drug
    UsageTier abbreviations appear next to drug entries to indicate cost‑sharing level
    inv-96: Requirement/limit legend — PA, QL, AL, LDD, 5DS, R, Q/T, MME
    Requirement/limit legendPA = Prior Authorization; QL = Quantity Limits Apply; AL = Age Limit; LDD = Limited Distribution Drug; 5DS = Day Supply Limit; R = Requires Rider; Q/T = Quantity Over Time; MME = Morphine Milligram Equivalent
    PurposeThese abbreviations indicate utilization controls applied to individual drug entries in the formulary
    inv-97: formulary_abbreviations — consolidated abbreviation definitions
    Consolidated abbreviationsPA, QL, SP, AL, LCG, LDD, 5DS, R, G, Q/T, PB, NPD, ACA, MME, + = Claim Dollar Limit
    Reference locationAbbreviations are summarized in the legend sections throughout the formulary document
    inv-98: PA abbreviation
    PA (abbreviation)Prior Authorization
    ContextUsed next to drug entries to indicate coverage requires prior authorization
    inv-99: QL abbreviation
    QL (abbreviation)Quantity Limits Apply
    ContextIndicates quantity restrictions on the drug/formulation
    inv-100: SP abbreviation
    SP (abbreviation)Specialty Drug
    ContextDesignates products requiring specialty handling or higher cost‑sharing
    inv-101: NPD abbreviation
    NPD (abbreviation)Non Preferred Drug
    ContextIndicates non‑preferred tier status which may affect cost‑sharing and PA requirements
    inv-102: G abbreviation
    G (abbreviation)Generic
    ContextDenotes generic tier placement on the formulary
    inv-103: LDD abbreviation
    LDD (abbreviation)Limited Distribution Drug
    ContextIndicates drugs with distribution limitations that may affect fulfillment pathways
    inv-104: Q/T abbreviation and related codes
    Q/T (abbreviation)Quantity Over Time
    5DS (abbreviation)Day Supply Limit (e.g., 5DS = 5‑day supply)
    MME (abbreviation)Morphine Milligram Equivalent — used to evaluate total daily opioid dose
    inv-105: Abbreviations used in drug list — consolidated abbreviations across multiple chunks
    Common abbreviations in drug listPA, QL, LDD, SP, PB, NPD, G, AL, 5DS, Q/T, MME, + = Claim Dollar Limit
    Where shownDisplayed in the requirements/limits column next to drug entries throughout the formulary
    inv-106: PA — Prior Authorization (definition instance)
    PA definition (legend instance)Prior Authorization
    UseIndicates that prior authorization is required for coverage of the drug/formulation
    inv-107: QL — Quantity Limits Apply (definition instance)
    QL definition (legend instance)Quantity Limits Apply
    UseIndicates quantity constraints appear on the drug entry
    inv-108: SP — Specialty Drug (definition instance)
    LDD definitionLimited Distribution Drug
    SP definitionSpecialty Drug
    ImplicationLDD and SP flags indicate special handling or distribution pathways for the product
    inv-109: NPD — Non Preferred Drug (definition instance)
    NPD definitionNon Preferred Drug
    PB definitionPreferred Brand
    ContextTier indicators affect cost‑sharing and may correlate with PA requirements
    inv-110: G — Generic (definition instance)
    G definitionGeneric
    PB definitionPreferred Brand
    UseTier labels used to communicate formulary placement and cost implications
    inv-111: PB — Preferred Brand (definition instance)
    PB definition (alt) Preferred Brand
    ContextAppears in the tier column to show preferred branded products
    inv-112: 5DS — Day Supply Limit (definition instance)
    5DS definitionDay Supply Limit (commonly 5DS = 5‑day supply)
    ImplementationDisplayed in requirements/limits to restrict day supply for certain products
    inv-113: MME — Morphine Milligram Equivalent (definition instance)
    MME definition (alt)Morphine Milligram Equivalent used to evaluate opioid daily dose
    Program useUsed to trigger prior authorization when daily opioid MME exceeds program threshold
    inv-114: PA (alt chunk) — Prior Authorization
    PA (alt) Prior Authorization
    QL (alt)Quantity Limits Apply
    LDD (alt)Limited Distribution Drug
    inv-115: QL (alt chunk) — Quantity Limits Apply
    QL (alt)Quantity Limits Apply
    SP (alt)Specialty Drug
    inv-116: LDD (alt chunk) — Limited Distribution Drug
    LDD (alt)Limited Distribution Drug
    PB (alt)Preferred Brand
    inv-117: PB/5DS/SP abbreviations (alt chunk)
    5DS (alt)Day Supply Limit
    SP (alt)Specialty Drug
    inv-118: NPD/G/LCG — alternate abbreviations
    NPD (alt)Non Preferred Drug
    G (alt)Generic
    LCGLow Cost Generic
    inv-119: MME/+ definitions
    MME (alt)Morphine Milligram Equivalent
    ++ = Claim Dollar Limit
    inv-120: legend — consolidated legend entry
    Legend summaryPA = Prior Authorization; QL = Quantity Limits Apply; SP = Specialty Drug; AL = Age Limit; LDD = Limited Distribution Drug; 5DS = Day Supply Limit; R = Requires Rider; Q/T = Quantity Over Time; ACA = $0 Preventive Drug; MME = Morphine Milligram Equivalent; + = Claim Dollar Limit
    UseThe legend appears repeatedly to define abbreviations used across the formulary drug list